Introduction
IL-6 is a pleotropic cytokine required for immune and inflammatory responses. IL-6 has been initially considered as a pro-inflammatory cytokines, and many of its pro-inflammatory properties are mediated by driving B cell activation and autoantibody production (Muraguchi et al., 1981; Hirano et al., 1986; Kishimoto et al., 1992) , inducing the expansion and activation of T cells (Le et al., 1988; Lotz et al., 1988; Okada et al., 1988) , and inducing chemokine expression and augmentation of ICAM-1 in endothelial cells (Romano et al., 1997) . IL-6 is a member of the IL-6 family cytokines (IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1)) and IL-6 receptor system consists of two molecules, IL-6Rα and gp130 (Taga and Kishimoto, 1997) . IL-6 binds to its binding receptor (IL-6Rα) devoid of signal transducing activity, and IL-6/IL-6Rα complex induces gp130 homodimerization, and dimerization of gp130 activates the receptor-associated protein tyrosine kinases, such as Jak1, Jak2, and Tyk2. Then, tyrosine residues in the cytoplasmic portion of gp130 are phosphorylated, and latent cytoplasmic Stat (signal transducer and activator of transcription) transcription factors are recruited to a phosphotyrosine-containing sequence in the cytoplasmic portion of gp130 and are tyrosine phosphorylated and activated. Activated Stat molecules dimerize and translocate to the nucleus, where they can activate transcription after binding to a consensus sequence in gene promoters (Darnell 1997;  15-Deoxy-12,14 -PGJ 2 inhibits IL-6-induced Stat3 phosphorylation in lym phocytes Taga et al., 1997) . In many cells, IL-6 activates predominantly Stat3, although Stat1 also can be activated. Activated Stat3 is involved in promoting T cell survival and functions (Takeda et al., 1998) .
15-deoxy-12,14 -PGJ2 (15d-PGJ2) is a natural ligand that activates the peroxisome proliferators-activated receptor γ (PPARγ), a member of nuclear receptor family and has been reported to exert anti-inflammatory activities in several kinds of cells such as macrophages and endotherial cells via PPARγ-dependent and -independent mechanism (Jiang et al., 1998; Ricote et al., 1998; Gilroy et al., 1999; Hinz et al., 2003; Imaizumi et al., 2003) . The precise mechanisms for anti-inflammatory effects of 15d-PGJ2 and other PPARγ agonists are poorly understood, and most recent studies about mechanisms for antiinflammatory action of 15d-PGJ2 and other PPARγ agonists have been focused on inhibiting nuclear factor κB (NF-κB) signaling pathway (Li et al., 2000; Rossi et al., 2000; Daynes and Jones, 2002) . The postulated mechanisms for suppression of inflammation are transrepression of the transcription factors such as NF-κB and activation protein 1 (AP-1) through the sequestration of essential, shared coactivators (Li et al., 2000; Daynes et al., 2002) and direct inhibition of IκB kinase by 15d-PGJ2 (Rossi et al., 2000) . To date, limited information is available for the interaction between the anti-inflammatory effects of PPARγ and cytokine-induced Jak-STAT signaling. Two studies were recently reported that 15d-PGJ2 exerts anti-inflammatory action via inhibition of IFNγ-induced Jak-STAT signaling pathway independent of PPARγ (Chen et al., 2003; Park et al., 2003) . In addition, Park et al. (2003) reported that 15d-PGJ2 induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which is the mechanism for 15d-PGJ2 induced inhibition of IFNγ signaling. There is no report about the modulation of cytokine-induced JakStat signaling by PPARγ in lymphocytes. In this study, we examined the effects of 15d-PGJ2 and other PPARγ agonists on cytokine-induced Jak-Stat signaling pathway in primary human lymphocytes, immortalized rheumatoid arthritis B cells and Jurkat human T cell line.
M aterials and M ethods C ell isolation and culture
Peripheral blood mononuclear cells (MNC) were obtained from three healthy blood donors by density gradient centrifugation using Ficoll Paque. Primary lymphocytes were purified from MNC by negative selection, using anti-CD14 magnetic beads, as recommended by the manufacturer (Miltenyi Biotech, Auburn, CA). Lymphocytes were used fresh in RPMI 1640 medium supplemented with 10% FBS. Jurkat human T cells and immortalized rheumatoid arthritis synovial B cells were also cultured at 37 o C in 5% CO2 using RPMI medium with 10% FBS. Immortalized rheumatoid arthritis synovial B cells were kindly provided by Dr. J. Sohn (Korea University, Seoul, Korea). These immortalized B cell lines were generated by Ebstein-Barr virus (EBV) transformation, a subsequent fusion with Sp2/0-Ag8 mouse myeloma cells and subcloning.
Im m unoblotting
Total cellular protein was extracted from several conditioned cells using Pro-prep protein extraction solution (Intron, Seoul, Korea). Extracts corresponding to 2 × 10 5 cells were separated through 7.5% SDSpolyacrylamide gels, transferred to polyvinylidene difluoride membranes by semidry electrophoretic transfer, and incubated with phospho-specific (Tyr705) antianti-Stat3 antibody, phospho-specific (Tyr701) antiStat1 antibody (Cell Signaling Technology, Beverly, MA), monoclonal anti-Stat3 antibody (Transduction Laboratories, Lexington, KY), and polyclonal antibody against human PPAR-γ (Santa Cruz, CA). ECL western blotting detection reagents (Amersham Biosciences) were used for detection.
Analysis of m RNA levels
Total cellular RNA was isolated using TRIzol reagent (Gibco BRL) according to the instructions of the manufacturer. For real-time PCR, RNA was treated with RNase-free DNAse (Gibco BRL), and complementary DNA (cDNA) was prepared by reverse transcription (RT) with a random hexamer primer (Invitrogen) and M-MuLV reverse transcriptase (Gibco BRL). Oligonucleotide primers used are as follows: GAPDH, AAGGTGAAGGTCGGAGTCAACG and CCT-TCTCCATGGTGGTGAAGAC; SOCS3, CACTCTTCA-GCATCTCTGTCGGAAG and CATAGGAGTCCAGGT-GGCCGTTGAC; SOCS1, AGGATGGTAGCACACAAC-CAGGT and GATCTGGAAGGGGAAGGAACTCAGGTA. We performed real time PCR using the iCycler iQ thermal cycler and detection system (Bio-Rad Laboratories). mRNA levels were normalized relative to GAPDH mRNA.
R esults 15d-PG J 2 inhibits IL-6-induced Stat activation in lym phocytes
In this study, the effects of 15d-PGJ2 on IL-6 signaling and Stat activation were examined using primary human lymphocytes, immortalized rheumatoid arthritis synovial B cells and Jurkat human T cells. Phosphorylation of Stat3 and Stat1 was induced rapidly by IL-6 treatment. To determine the effects of 15d-PGJ2 on IL-6-induced Stat phosphorylation, the cells were pretreated with 10 µM 15d-PGJ2 for 2 h, followed by IL-6 stimulation for 10 min at 37 o C in 5% CO2. IL-6 activates predominantly Stat3, and activated Stat3 is mainly involved in promoting T cell survival and functions (Takeda et al., 1998) . So, in this study, we focused primarily the modulation of 15d-PGJ2 on
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IL-6-induced Stat3 phosphorylation. Two hours' pretreatment with 15d-PGJ2 inhibited Stat3 and Stat1 phosphorylation in primary human lymphocytes (Figure 1A) . Similar to IL-6, IL-10 activation of Stat3 was inhibited by 15d-PGJ2 at tyrosine-phosphorylation level. However, in this study, we investigated mainly about the modulation of IL-6-induced Stat3 phosphorylation by 15d-PGJ2. Also we used immortalized rheumatoid arthritis B cells and Jurkat human T cells for studying the effects of 15d-PGJ2 on IL-6-induced signaling, and these results were compared with the results from primary lymphocytes. Jurkat cells were shown not to express IL-6Rα (Igaz et al., 2000) , so we used combination of IL-6 and soluble IL-6 receptor (sIL-6R) for examining the IL-6 signaling in Jurkat cells. 15d-PGJ2 could inhibit Stat3 phosphorylation in immortalized rheumatoid arthritis B cells and Jurkat human T cells, too ( Figure 1B, 1C) . In unstimulated conditions, weak phosphorylation of Stat3 was seen in rheumatoid arthritis B cells, we can guess minimal production of some cytokines from rheumatoid arthritis B cells, but we did not examine this. 15d-PGJ2 mediated-inhibition of IL-6 signaling was in a dose-dependent manner ( Figure 1D, 1E ). In contrast, phosphorylation of Stat1 by IFN-γ was not inhibited by 10 µM 15d-PGJ2 ( Figure 1A ). This result is distinct from those reported by Park et al. (2003) and Chen et al. (2003) who showed that 10 µM of 15d-PGJ2 significantly suppresses IFN-γ signaling in murine macrophages and rat astrocytes. But very high concentrations of 15d-PGJ2 can inhibit IFN-γ signaling ( Figure 1F ). So, we demonstrated here that 15d-PGJ2 also can inhibit IFN-γ signaling in a dose-dependent manner. These results indicate that IL-6-induced Stat3 phosphorylation is more easily inhibited by 15d-PGJ2 as compared with IFN-γ-induced Stat1 phosphorylation and also suggest that the inhibition of cytokine signaling using the Jak-Stat pathway by 15d-PGJ2 may be different in the several cell types.
Alcohol inhibits cytokine-induced Stat activation (Chen et al., 1999) . Since we used ethanol for dissolving 15d-PGJ2, we tested the effects of ethanol on IL-6 and IFNγ signaling in lymphocytes. Low concentration of ethanol (20 µM) which we used to dissolve 15d-PGJ2, as compared with the previous report (Chen et al., 1999) did not inhibit IFN-γ signaling as well as IL-6 signaling (Data not shown) in lymphocytes.
To exclude the possibility that cell death may contribute to the decreased Stat phosphorylation, trypan blue staining was used to quantify the numbers of viable cells. Treatment with 15d-PGJ2 for 2 h resulted in a less than 10% decrease in the number of viable 15d-PG J 2 induced-inhibition of IL-6 signaling occurs rapidly and is independent of de novo gene expression We investigated the mechanism about 15d-PGJ2 induced inhibition of IL-6 signaling. The currently known mechanisms for inhibition of Jak-Stat signaling are via de novo expression of SOCS (Yasukawa et al., 2000) and a rapid, direct inhibitory pathway that is dependent upon protein kinase C (PKC) or m itogenactivated protein kinases (MAPK) (Lee et al., 1999; Ahmed and Ivashkiv, 2000; Ji et al., 2003) . The requirement for de novo production of IL-6 signaling inhibitors was investigated by examining the kinetics of inhibition, and by using actinomycin D and cycloheximide to inhibit de novo transcription and translation. To determine the time course of 15d-PGJ2 inhibitory effects on IL-6-induced Stat3 phosphorylation, primary lymphocytes were incubated with 10 µM 15d-PGJ2 for various times. 15d-PGJ2 inhibited IL-6 signaling strongly when added just 15 min prior to IL-6 (Figure 2A ), suggesting that 15d-PGJ2 stimulates a direct, very rapid inhibitory pathways or induces a inhibitor within 15 min. Inhibition of IL-6 signaling was preserved when de novo gene expression was blocked using actinomycin D ( Figure 2B ). However, when we used cycloheximide for blocking de novo protein synthesis, 15d-PGJ2 induced-inhibition of IL-6 signaling was partially reversed by cycloheximide ( Figure  2B ). Recent report shows that cycloheximide can activate p38 in monocytes (Ahmed et al., 2002) . Therefore, we can guess that the reversal of inhibited IL-6 signaling by cycloheximide does not occur secondary to inhibition of de novo protein synthesis, but instead we can suggest that the effect of 15d-PGJ2 on IL-6 signaling may be directly inhibited by cycloheximide via other pathway, such as p38.
Inhibition of Jak-Stat signaling has been proposed to occur by rapid and direct inhibitory pathway dependent upon MAPKs, phosphatase or PKC. Recent study suggests that 15d-PGJ2 stimulates the expression of IL-8 gene in THP-1 macrophages through a MAPK signaling pathway (Fu et al., 2002) . The role of MAPKs, phosphatase or PKC in inhibition of IL-6 signaling was investigated using specific inhibitors of these kinases. Inhibitor of PKC (GF109203X) by itself suppressed IL-6-induced Stat3 phosphorylation ( Figure 2C ). So we could not definitively rule out the possibility of PKC involvement in 15d-PGJ2 induced inhibition of IL-6 signaling. But inhibitors of ERKs (PD98059), p38 (SB203580), and phosphatase (sodium orthovanadate) had no effect on the IL-6-induced Stat3 phosphorylation by themselves (data not shown). PD98059, SB203580, and sodium orthovanadate did not influence 15d-PGJ2 induced inhibition of IL-6 signaling ( Figure 2C ), indicating that MAPKs and phosphatase may be not involved in 15d-PGJ2-induced inhibition of IL-6 signaling.
Also we tested 15d-PGJ2-induced SOCS3 expression in lymphocytes, using real time PCR. Recently, Yu et al. (2003) reported that SOCS3 are constitutively expressed in murine naive T cells. 15d-PGJ2 did not induce SOCS3 expression in primary lymphocytes and Jurkat cells ( Figure 2D ). In contrast, 15d-PGJ2 inhibited SOCS3 expression in primary human lymphocytes ( Figure 2D ). These results indicate that 15d-PGJ2-induced-inhibition of IL-6 signaling is independent of the expression of new genes, such as SOCS3.
15d-PG J2 inhibits IL-6-induced Jak-Stat signaling via PPARγ-independent m echanism
Previous studies demonstrated that 15d-PGJ2 exerts anti-inflammatory action via PPARγ-independent mechanism (Hinz et al., 2003) , and inhibition of IFNγ-induced Jak-Stat signaling is independent of PPARγ (Chen et al., 2003; Park et al., 2003) . So we investigated whether PPARγ mediates the inhibitory action of 15d-PGJ2 on IL-6-induced Jak-Stat signaling. First we determined the presence of PPARγ in primary human lymphocytes, Jurkat human T cells and immortalized rheumatoid arthritis B cells. PPARγ could be detected in all three cell types ( Figure 3A) . Then we compared the inhibitory effects of different PPARγ agonists on IL-6 signaling. 15d-PGJ2 but not other PPARγ agonists inhibits IL-6 signaling in primary human lymphocytes ( Figure 3B ). Our results suggest that inhibition of IL-6 signaling by 15d-PGJ2 in lymphocytes is mediated via PPARγ-independent mechanism.
IL-6 inhibits SOCS3 expression in Jurkat cells and this inhibition is reversed by 15d-PG J 2
We assessed the functional significance of 15d-PGJ2 -induced inhibition of IL-6 signaling, by exam ining the effects of 15d-PGJ2 on IL-6-induced change of SOCS3 expression. SOCS3 gene was expressed in Jurkat cells without any stimulation. Previous reports demonstrated that IL-6 induced SOCS3 expression in HepG2 cells and mouse liver (Starr et al., 1997; Senn et al., 2004) . Unexpectedly, in our results, treatment of IL-6 for 3 h decreased the expression of SOCS3. IL-6 induced inhibition of SOCS3 expression was reversed by pretreatment of 15d-PGJ2 (Figure 4) . Thus, this result showed that inhibition of IL-6 signaling by 15d-PGJ2 resulted in suppression of IL-6 functional activity.
D iscussion
After two reports about anti-inflammatory effects of PPARγ were published (Jiang et al., 1998; Ricote et al., 1998) , PPARγ agonists have been focused on research fields studying inflammation. The inhibitory effect of PPARγ agonists on Stat molecules was previously suggested (Ricote et al., 1998) . However, most studies about anti-inflammatory action of PPARγ have been focused on inhibiting NFκB signaling pathway. Thus we studied the effects of PPARγ agonists on Jak-Stat signaling pathway. Park et al. (2003) reported that 15d-PGJ2 and rosiglitazone are potent inducers of SOCS expression in primary astrocytes, and that the inhibition of IFN-γ signaling by 15d-PGJ2 is dependent of induction of SOCS expression. But here we show that 15d-PGJ2-induced inhibition of IL-6 signaling is independent of de novo gene expression and 15d-PGJ2 can not induce SOCS3 in lymphocytes. Also, in our experiments, other well known mechanisms for inhibition of Jak-STAT signaling, such as MAPKs, phosphatase were not involved in 15d-PGJ2-induced inhibition of IL-6 signaling. Therefore, we cannot rule out the possibility that unknown rapid, direct inhibitory pathway may be involved in 15d-PGJ2-induced inhibition of IL-6 signaling, and further experiments about the unknown mechanisms of 15d-PGJ2-induced inhibition of IL-6 signaling need to be done. Many studies described a role of PPARγ for control of inflammation in the monocyte/macrophage. However, as yet, there have been very few reports about a role for PPARγ in the lymphocytes. Clark et al. (2000) described the expression and function of PPARγ in T lymphocytes. They demonstrated that murine T cell expresses PPARγ. In this study, they also demonstrated 15d-PGJ2 and ciglitazone mediate significant inhibition of proliferative responses of both the T cell clones and the freshly isolated splenocytes, but did not inhibit IL-2-induced proliferation of such clones. They suggest 15d-PGJ2 and ciglitazone may affect signaling pathway involved in T cell receptor stimulation but not IL-2-induced signaling pathway. In our study, 15d-PGJ2 inhibits IL-6-induced Stat activation but not IFN-γ induced Stat activation at the same concentration. So we can suggest that 15d-PGJ2 modulate specifically Jak-Stat signaling of individual cytokines in lymphocytes. Yang et al. (Yang et al., 2000) showed that PPARγ mRNA was expressed in human peripheral blood T lymphocytes and 15d-PGJ2 inhibited IL-2 production and phytohemagglutinin-inducible proliferation in human peripheral blood T-cells in a dose-dependent manner. Also they showed wildtype Jurkat cells expressed little detectable PPARγ mRNA and PPARγ-transfected Jurkat cells but not wild-type were inhibited in IL-2 secretion by PPARγ ligands. These results indicated that in T cells, 15d-PGJ2 and troglitazone mediate their effects only through PPARγ-dependent pathways. In our study, we detected a strong PPARγ expression in Jurkat cells by Western blot and 15d-PGJ2 inhibited IL-6 signaling in wild-type Jurkat cells. Also we showed that other PPARγ agonists did not inhibit IL-6 signaling in lymphocytes, so these result suggest 15d-PGJ2 maybe mediate its effect through PPARγ-independent mechanism. We need further studies about PPARγ-dependent and independent pathway of several PPARγ ligands in lymphocytes
The demonstration that 15d-PGJ2 specifically inhibits Jak-STAT signaling pathway in lymphocytes may expand the possible immunoregulatory role of 15d-PGJ2 and other PPARγ agonists. Taken together with the effects of 15d-PGJ2 and other PPARγ agonists on macrophage function, our results suggest that 15d-PGJ2 may play a significant role in the lymphocyte. Also our findings demonstrated that 15d-PGJ2 can regulate inflammatory reactions through the modulation of different signaling pathway other than NF-κB.
